ECHDC2

Across TCGA pan-cancer cohorts, ECHDC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECHDC2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ECHDC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ECHDC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, UCEC, and GBM are the cancer types where ECHDC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.892	.004	19	view →
UCEC	DFS	Quartile	II,III,IV	0.351	0.853	.037	8	view →
GBM	OS	Median	All	0.263	0.456	.008	7	view →
LUAD	DFS	Quartile	III,IV	0.389	0.788	.041	3	view →
PDAC	OS	Quartile	II,III,IV	0.953	0.787	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ECHDC2–CCRCC (OS)

Open the CCRCC breakdown →